Gilead Sciences Inc. closed $6.85 short of its 52-week high ($98.90), which the company achieved on November 11th.
Padlock Therapeutics investors accused Bristol Myers of avoiding making milestone payments promised under a 2016 deal.
Zacks.com on MSN14h
Gilead (GILD) Upgraded to Buy: Here's WhyGilead Sciences (GILD) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- ...
Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent ...
Gilead is going to start testing a drug it believes could prevent HIV infection with just a single shot every year.
Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...
Gilead Sciences has raided Sanofi for its next chief medical officer, luring Dietmar Berger, M.D., Ph.D., away from the ...
Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $91.86 which represents a decrease of $-0.52 or -0.56% from the prior close of $92.38. The stock opened at $91.66 and touched a low ...
For years, Gilead Sciences was dead money for shareholders. Shares of the drugmaker, with a market capitalization of just ...
At the HIV Analyst & Investor Event on Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) revealed that it is developing a ...
Gilead Sciences Inc. closed $7.05 short of its 52-week high ($98.90), which the company reached on November 11th.
Gilead isn’t the only Big Pharma to take an interest in Tubulis’ ADC tech. BMS paid the company $23 million upfront in April ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback